银屑病和其治疗相关的肿瘤患病风险(3)
[36] Pariser DM,Leonardi CL,Gordon K, safety analysis:Short and long term safety profiles of etanercept in patients with psoriasis[J].J Am Acad Dermatol,2012,67(2):245-256.
[37] Kimball AB,Rothman KJ,Kricorian G,:Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results[J].J Am Acad Dermatol,2015,72(1):115-122.
[38] Menter A,Tha?i D,Wu JJ, safety and effectiveness of adalimumab for moderate to severe psoriasis:Results from 7-year interim analysis of the ESPRIT registry[J].Dermatol Ther (Heidelb),2017,7(3):365-381.
[39] Mariette X,Matucci-Cerinic M,Pavelka K, associated with tumour necrosis factor inhibitors in registries and prospective observational studies:A systematic review and meta-analysis[J].Ann Rheum Dis,2011,70(11):1895-1904.
[40] Askling J,Fahrbach K,Nordstrom B, risk with tumor necrosis factor alpha(TNF) inhibitors:Meta-analysis of randomized controlled trials of adalimumab,etanercept,and infliximab using patient level data[J].Pharmacoepidemiol Drug Saf,2011,20(2):119-130.
[41] Scott FI,Mamtani R,Brensinger CM, of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer[J].JAMA Dermatol,2016,152(2):164-172.
[42] Raaschou P,Simard JF,Asker Hagelberg C, arthritis,anti-tumour necrosis factor treatment,and risk of squamous cell and basal cell skin cancer:Cohort study based on nationwide prospectively recorded data from Sweden[J].BMJ,2016,352:i262.
[43] van Lümig PP,Menting SP,van den Reek JM,etal.An increased risk of nonmelanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors[J].J Eur Acad Dermatol Venereol,2015,29(4):752-760.
[44] Mercer LK,Askling J,Raaschou P, of invasive mela-noma in patients with rheumatoid arthritis treated with biologics:results from a collaborative project of 11 European biologic regi-sters[J].Ann Rheum Dis,2017,76(2):386-391.
[45] Olsen CM,Hyrich KL,Knight LL, risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors:A systematic review and meta-analysis[J].Melanoma Res,2016,26(5):517-523.
[46] Raaschou P,Simard JF,Holmqvist M, arthritis,anti-tumour necrosis factor therapy,and risk of malignant mela-noma:Nationwide population based prospective cohort study from Sweden[J].BMJ,2013,346:f1939.
[47] Long MD,Martin CF,Pipkin CA, of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease[J].Gastroenterology,2012,143(2):
[48] Nardone B,Hammel JA,Raisch DW, associated with tumour necrosis factoralpha inhibitors:A research on adverse drug events and reports (RADAR) project[J].Br J Dermatol,2014,170(5):1170-1172.
[49] Burmester GR,Panaccione R,Gordon KB,:Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis,juvenile idiopathic arthritis,ankylosing spondylitis,psoriatic arthritis,psoriasis and Crohn′s disease[J].Ann Rheum Dis,2013,72(4):517-524.
[50] Leonardi C,Papp K,Strober B,etal.The long-term safety of adalimumab treatment in moderate to severe psoriasis:A comprehensive analysis of all adalimumab exposure in all clinical trials[J].Am J Clin Dermatol,2011,12 (5):321-337.
[51] Magnano M,Loi C,Sechi A, of malignancy in psoriatic patients:Our clinical experience[J].Dermatol Ther,2017,30(4):Epub 2017.
[52] Napolitano M,Megna M,Patrì A, treatment for psoriasis and malignancies:A real risk?[J].Dermatol Ther,2017,30(4).Epub 2017.
[53] Trinchieri and the regulation of innate resistance and adaptive immunity[J].Nat Rev Immunol,2003,3(2):133-146.
[54] Zou W,Restifo NP.T(H)17 cells in tumour immunity and immunotherapy[J].Nat Rev Immunol,2010,10(4):248-256.
[55] Furqan M,Mukhi N,Lee B, of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application[J].Biomark Res,2013,1(1):5.
[56] Suhasini AN,Wang L,Holder KN,etal.A phosphodiesterase 4B-dependent interplay betweentumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma[J].Leukemia,2016,30(3):617-626.
[57] Pullamsetti SS,Banat GA,Schmall A, promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF[J].Oncogene,2013,32(9):1121-1134.
[58] Shelton E,Laharie D,Scott FI, recurrence following immune-suppressive therapies in patients with immune-mediated diseases:A systematic review and Meta-analysis[J].Gastroenterology,2016,151(1):97-109.
[59] Silva-Fernández L,Lunt M,Kearsley-Fleet L,etal.The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab:Results from the British society for rheumatology biologics register-rheumatoid arthritis[J].Rheumatology (Oxford),2016,55(11):2033-2039.
[60] Polesie S,Gillstedt M,Paoli J, treatment in patients with a history of cutaneous melanoma and the risk of a consecutive primary melanoma:A national retrospective registry-based cohort study[J].J Am Acad Dermatol,2017,77(1):161-163.
文章来源:《中国肿瘤生物治疗杂志》 网址: http://www.zgzlswzlzz.cn/qikandaodu/2020/1120/459.html
上一篇:冬虫夏草,科学的笑话
下一篇:糖尿病肾病的生物治疗及研究进展